Enter MED-C. Personalized medicine needs data – lots of it. After consulting with leaders in each of medicine’s major groups, we are developing a registry of genomic data and clinical outcomes from treatments of patients diagnosed with cancer. This data will be readily accessible to physicians, researchers, pharmaceutical companies, regulators and insurance companies.
As the registry grows, so will its benefits to each of these groups. But above all: Medical care will become more accurate and precise, time and resources will be better used, money will be put to better use, and more lives will be saved.
MED-C is creating a registry focused on genetic-data collection. Doctors and pharmaceutical companies will have access to this high-quality-standard genetic testing, also known as Next Generation Sequencing.
MED-C is establishing standards by which all laboratory testing will be carried out and reported. This will allow data to be compared side-by-side and allow a more rapid accumulation of cases to study.
MED-C will assemble not only richly detailed laboratory data from genetic-level testing but clinical outcomes matched to that data: In other words, this combination of conditions treated by these methods led to this result.
MED-C is a nonprofit organization committed to making its data and information as accessible as possible to physicians, researchers, insurance and pharmaceutical companies and regulators.